Buyout shop Linden Capital Partners is paying roughly $80.8 million to buy SeraCare Life Sciences Inc., Reuters reported. The $4.00-per-share deal represents a premium of nearly 12% to SeraCare’s Friday’s close on the Nasdaq. SeraCare supplies diagnostic control products for HIV, plasma-derived reagents and contract research services.
(Reuters) – SeraCare Life Sciences Inc said it will be bought by an affiliate of private equity firm Linden Capital Partners for $80.8 million.
The $4.00-per-share deal represents a premium of nearly 12 percent to SeraCare’s Friday’s close on the Nasdaq. SeraCare had 20.2 million shares outstanding as of Feb. 3.
SeraCare, which supplies diagnostic control products for HIV, plasma-derived reagents and contract research services, had said last year it was exploring strategic alternatives, including a possible sale, after it received an unsolicited buyout offer from private equity firm MSMB Capital.
The deal is expected to close in the second quarter if approved by shareholders, SeraCare said in a statement on Monday.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.